---
document_datetime: 2025-01-06 13:49:08
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/duavive-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: duavive-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.6215566
conversion_datetime: 2025-12-25 01:41:10.424006
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Duavive

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0040              | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF | 19/11/2024                          | n/a                                         |                                  |           |
| IA/0039              | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process      | 01/10/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------|
| IA/0038 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                               | 01/10/2024 | n/a        |             |                 |
| II/0036 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                        | 02/05/2024 | 24/07/2024 | SmPC and PL |                 |
| IA/0037 | B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                                               | 04/12/2023 | n/a        |             |                 |
| IB/0035 | B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                                                                                                                                                        | 19/06/2023 | 24/07/2024 | SmPC and PL |                 |
| II/0032 | Submission of an updated RMP version 3.4 in order to reflect the updated study milestones and completion of the post authorisation safety study of CE/BZA in the United States (US PASS, Study B2311060) previously assessed as part of II/0030 (MEA002.15), as well as to update the post marketing data with the data lock point of 31 October 2021 and the final sign off date 03.03.2023. C.I.11.b - Introduction of, or change(s) to, the conditions of a marketing | 12/05/2023 | n/a        |             | obligations and |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10321 /202204 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 01/12/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                              |
| IB/0033/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 19/07/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                |
| II/0030             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/12/2021 | 16/12/2022 | SmPC and PL | The aim of this PASS study was to estimate the incidence and to compare some risks (i.e. endometrial hyperplasia, endometrial cancer) among postmenopausal women initiating either CE/BZA or E+P HRT. The results of the study show that the risk of breast cancern and stroke might be in the same range as among users of estrogen-progestin |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |    | combination hormone therapy. The corresponding incidence rates are stated in the SmPC section 5.1.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------------------------------------------------------------------------------------|
| N/0031  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/10/2021 | 16/12/2022 | PL |                                                                                                      |
| N/0029  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/12/2020 | 10/05/2021 | PL |                                                                                                      |
| II/0025 | Submission of the final clinical study report (CSR) for the Duavive Non-Interventional EU Drug Utilisation Study (DUS) - Study B2311061. This final CSR relates to the Post-Authorisation Measure MEA 003. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                            | 03/09/2020 | n/a        |    |                                                                                                      |
| II/0024 | Update of the Risk Management Plan (RMP) to version 3.1, to include amended study milestones and to revise the RMP document format in line with latest Good Pharmacovigilance Practices Guidance Module V, revision 2 guidelines, as requested during the assessment of the renewal. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 03/09/2020 | n/a        |    |                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0028             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 26/08/2020   | 10/05/2021   | SmPC and PL                      |                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 10/06/2020   | n/a          |                                  |                                                                                                                                                                                                                                                                       |
| IB/0026             | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                         | 14/05/2020   | 10/05/2021   | SmPC and PL                      |                                                                                                                                                                                                                                                                       |
| R/0021              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 19/09/2019   | 11/11/2019   | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Duavive in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10321 /201904 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                           | 31/10/2019   | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| N/0022              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 09/04/2019   | 11/11/2019   | PL                               |                                                                                                                                                                                                                                                                       |
| IA/0020             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 07/02/2019   | n/a          |                                  |                                                                                                                                                                                                                                                                       |
| IA/0019             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                          | 17/12/2018   | n/a          |                                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                     |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10321 /201804 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                         | 31/10/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0018              | Transfer of Marketing Authorisation                                                                                                                                                                                                        | 11/07/2018 | 02/08/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10321 /201704 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                         | 26/10/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0016              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 10/10/2017 | 24/01/2018 | Labelling and PL       |                                   |
| IB/0014             | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 21/02/2017 | 24/01/2018 | SmPC and PL            |                                   |
| N/0013              | Update of the package leaflet with revised contact details of the local representative for Germany. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                       | 28/10/2016 | 24/01/2018 | PL                     |                                   |
| PSUSA/10321 /201604 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                         | 27/10/2016 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0011           | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                             | 19/04/2016 | 08/09/2016 | SmPC and PL            |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |      |                                                                                                                                                                                                                     |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10321 /201510 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/04/2016 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                   |
| N/0010              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                             | 31/03/2016 | 08/09/2016 | PL   |                                                                                                                                                                                                                     |
| N/0009              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                             | 04/02/2016 | 08/09/2016 | PL   |                                                                                                                                                                                                                     |
| IB/0008             | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                                                                                                                                  | 02/02/2016 | n/a        |      |                                                                                                                                                                                                                     |
| IAIN/0007/G         | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 11/01/2016 | n/a        |      |                                                                                                                                                                                                                     |
| II/0002             | Update of sections 4.5 and 5.2 of the SmPC based on clinical drug-drug interaction study B2311065 undertaken to evaluate the effects of the strong CYP3A4 inhibitor, itraconazole, on the                                                                                                                                                                                                                                                                                                                    | 19/11/2015 | 08/09/2016 | SmPC | In vitro and in vivo studies have shown that oestrogens are partially metabolized by cytochrome P450 enzymes, including CYP3A4. However, in a clinical drug drug interaction study, repeat administration of 200 mg |

<div style=\"page-break-after: always\"></div>

|                     | pharmacokinetics of CE 0.45 mg/BZA 20 mg. The provision of the study report addresses the post- authorisation measure MEA 001. In addition, the MAH took the opportunity to update section 5.1 of the SmPC with the assigned pharmacotherapeutic group and ATC code. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | itraconazole, a strong CYP3A4 inhibitor, had minimal impact on the pharmacokinetics of CE (as measured by estrone and equilin) and bazedoxifene when administered with a single dose of CE 0.45 mg/bazedoxifene 20 mg. In a pharmacokinetic study (n=24) BMI appeared to have little impact on systemic exposure to CE and bazedoxifene.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                           | 16/11/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10321 /201504 | Periodic Safety Update EU Single assessment - oestrogens conjugated / bazedoxifene                                                                                                                                                                                                                                                                                                       | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                          |
| II/0004             | Update of section 4.8 of the Smpc to include revised frequency categories of a number of ADRs for the bazedoxifene monotherapy component. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                            | 17/09/2015 | 08/09/2016 | SmPC and PL | The frequency categories have changed as follows: Retinal vein thrombosis from 'rare' to 'uncommon'; rash, pruritus from 'not known' to 'common'; oedema peripheral from 'common' to 'very common'.                                                                                                                                        |
| N/0001              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                         | 24/06/2015 | 08/09/2016 | PL          |                                                                                                                                                                                                                                                                                                                                            |